Back to Search
Start Over
Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma
- Source :
- Pancreatology. 18:671-677
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- To evaluate the prediction of benefits from adjuvant chemoradiotherapy by postoperative serum CA19-9, CA125 and CEA.The relations between benefits from adjuvant chemoradiotherapy and levels of postoperative serum CA19-9, CA125 and CEA were investigated in 804 pancreatic adenocarcinoma patients who received radical resection.Adjuvant chemoradiotherapy was an independent factor for late recurrence [12.2 vs. 8.5 months, P = 0.001 for recurrence free survival (RFS)] and long survival [23.7 vs. 17.0 months, P 0.001 for overall survival (OS)] in resected pancreatic adenocarcinoma. Postoperative serum CA19-9, CA125 and CEA were independent risk predictors for poor surgical outcome in pancreatic adenocarcinoma (P 0.001 for all). Adjuvant chemradiotherapy (hazard ratio: 0.359, 95% confidence interval: 0.253-0.510, P 0.001 for OS; hazard ratio: 0.522, 95% confidence interval: 0.387-0.705, P 0.001 for RFS) were confirmed to improve the surgical outcome in patients with abnormal levels of any one of the three postoperative markers, but not in patients with normal levels of the three postoperative markers. In the subgroup of patients with negative lymph node, its improvement of surgical outcome was also significant in patients with abnormal levels of any one of postoperative serum CA19-9, CA125 and CEA (hazard ratio: 0.412, 95% confidence interval: 0.244-0.698, P = 0.001 for OS; hazard ratio: 0.546, 95% confidence interval: 0.352-0.847, P = 0.007 for RFS).Postoperative serum CA19-9, CA125 and CEA could serve as predictors of response for adjuvant chemoradiotherapy even if the status of lymph nodes is negative.
- Subjects :
- Adult
Male
medicine.medical_specialty
CA-19-9 Antigen
endocrine system diseases
Endocrinology, Diabetes and Metabolism
Kaplan-Meier Estimate
Adenocarcinoma
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Internal medicine
Recurrence free survival
Late Recurrence
Biomarkers, Tumor
Humans
Medicine
Postoperative Period
030212 general & internal medicine
Adjuvant chemoradiotherapy
Aged
Aged, 80 and over
Hepatology
business.industry
Membrane Proteins
Chemoradiotherapy, Adjuvant
Middle Aged
medicine.disease
Survival Analysis
Progression-Free Survival
digestive system diseases
Independent factor
Carcinoembryonic Antigen
Pancreatic Neoplasms
Treatment Outcome
CA-125 Antigen
030220 oncology & carcinogenesis
Female
CA19-9
Lymph Nodes
Lymph
business
Radical resection
Follow-Up Studies
Subjects
Details
- ISSN :
- 14243903
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Pancreatology
- Accession number :
- edsair.doi.dedup.....3c50ed5f5ddd3c2db858b0a403a442ca